Targeting tumors with advanced CAR T cell technology
Precise tumor targeting with logic CAR circuits
['FUNDING_U01'] · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · NIH-10899548
This study is exploring a new type of CAR T cell therapy that helps your immune cells better find and attack cancer cells while protecting healthy ones, making it a safer and more effective option for people with cancer.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10899548 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel CAR T cell therapy that uses a programmable system to precisely target tumors while minimizing damage to healthy tissues. By employing a unique SUPRA CAR system, the study aims to enhance the ability of T cells to recognize and respond to cancer cells while avoiding off-tumor toxicity. The approach involves testing different logic circuits that allow T cells to differentiate between cancerous and healthy cells, ensuring a more effective and safer treatment for patients. The research will utilize advanced techniques in synthetic biology and immunology, with experiments conducted in mouse models to validate the effectiveness of this therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with specific types of cancers that are targeted by the CAR T cell therapy being developed.
Not a fit: Patients with cancers that do not express the targeted antigens or those who are not eligible for CAR T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective CAR T cell therapies for cancer patients.
How similar studies have performed: Other research has shown promise in using advanced CAR T cell technologies, suggesting that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
BOSTON, UNITED STATES
- BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WONG, WILSON — BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
- Study coordinator: WONG, WILSON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.